GI
CRBP icon

GAMMA Investing’s Corbus Pharmaceuticals CRBP Stock Holding History

GAMMA Investing’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.15K Hold
336
– – ﹤0.01% 3634
2026
Q1 		$3.15K Sell
336
-50
-13% -$421 ﹤0.01% 3539
2025
Q4 		$3.14K Hold
386
– – ﹤0.01% 3462
2025
Q3 		$4.88K Buy
386
+50
+15% +$476 ﹤0.01% 3194
2025
Q2 		$2.32K Sell
336
-120
-26% -$872 ﹤0.01% 3367
2025
Q1 		$2.42K Buy
456
+250
+121% +$2.21K ﹤0.01% 3355
2024
Q4 		$2.43K Buy
206
+196
+1,960% +$3.29K ﹤0.01% 3161
2024
Q3 		$206 Buy
+10
New +$512 ﹤0.01% 3495

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

GAMMA Investing's CRBP Position: Q2 2026 in Review

GAMMA Investing held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 336 shares worth $3.15K. The position accounts for ﹤0.01% of the portfolio, ranked #3634.

GAMMA Investing first reported a position in CRBP in Q3 2024 and has held it in 8 quarters since. The position peaked at $4.88K in Q3 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • GAMMA Investing held 336 shares of Corbus Pharmaceuticals worth $3.15K as of Q2 2026.
  • GAMMA Investing left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3634 holding.
  • GAMMA Investing first reported a position in Corbus Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • GAMMA Investing's Corbus Pharmaceuticals position peaked at $4.88K in Q3 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.